Skip to main content
SpringerLink
Log in
Book cover

Critical Issues in Head and Neck Oncology pp 251–265Cite as

Cytotoxic Chemotherapy and Targeted Therapy in Nasopharyngeal Cancer

  • Chapter
  • First Online:

  • 432 Accesses

Abstract

Over the past several decades, there has been a notable decrease in the incidence and mortality of nasopharyngeal carcinoma. Lifestyle modification, improvements in screening and diagnosis, and advances in radiation and systemic therapy have all contributed to these favorable trends. In this chapter, we review current treatment methods in localized and recurrent/metastatic disease, with an emphasis on systemic therapy. Additionally, we explore the potential role of Epstein-Barr virus in determining treatment strategy and evaluate newer targeted therapies, including immunotherapy, which may become standard treatment options in the future.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):359.

    Article  Google Scholar 

  2. Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomark Prev. 2006;15(10):1765–77.

    Article  CAS  Google Scholar 

  3. Tang L, Chen W, Xue W, et al. Global trends in incidence and mortality of nasopharyngeal carcinoma. Cancer Lett. 2016;374(1):22–30.

    Article  CAS  Google Scholar 

  4. Nicholls JM. Nasopharyngeal carcinoma: classification and histologic appearances. Adv Anat Pathol. 1997;4(2):71–84.

    Article  Google Scholar 

  5. Barnes L, Eveson JW, Reichart P, Sidransky D. World Health Organization classification of tumours. Pathology and genetics of head and neck tumours. Lyon: International Agency of Research on Cancer; 2005.

    Google Scholar 

  6. Maxwell JH, Kumar B, Feng FY, et al. HPV-positive/p16-positive/EBV-negative nasopharyngeal carcinoma in white North Americans. Head Neck. 2010;32(5):562–7.

    PubMed  PubMed Central  Google Scholar 

  7. Lin Z, Khong B, Kwok S, et al. Human papillomavirus 16 detected in nasopharyngeal carcinomas in white Americans but not in endemic Southern Chinese patients. Head Neck. 2014;36(5):709–14.

    Article  Google Scholar 

  8. Huang WB, Chan JYW, Liu DL. Human papillomavirus and World Health Organization type III nasopharyngeal carcinoma: multicenter study from an endemic area in Southern China. Cancer. 2018;124(3):530–6.

    Article  Google Scholar 

  9. Dogan S, Hedberg ML, Ferris RL, Rath TJ, Assaad AM, Chiosea SI. Human papillomavirus and Epstein-Barr virus in nasopharyngeal carcinoma in a low-incidence population. Head Neck. 2014;36(4):511–6.

    Article  Google Scholar 

  10. Stenmark MH, McHugh JB, Schipper M, et al. Nonendemic HPV-positive nasopharyngeal carcinoma: association with poor prognosis. Int J Radiat Oncol Biol Phys. 2014;88(3):580–8.

    Article  Google Scholar 

  11. Tse K, Su W, Chang K, et al. Genome-wide association study reveals multiple nasopharyngeal carcinoma-associated loci within the HLA region at chromosome 6p21.3. Am J Hum Genet. 2009;85(2):194–203.

    Article  CAS  Google Scholar 

  12. Bei J, Li Y, Jia W, et al. A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat Genet. 2010;42(7):599.

    Article  CAS  Google Scholar 

  13. Hsu W, Tse K, Liang S, et al. Evaluation of human leukocyte antigen-A (HLA-A), other non-HLA markers on chromosome 6p21 and risk of nasopharyngeal carcinoma. PLoS One. 2012;7(8):e42767.

    Article  CAS  Google Scholar 

  14. Chua ML, Wee JT, Hui EP, Chan AT. Nasopharyngeal carcinoma. Lancet. 2016;387(10022):1012–24.

    Article  Google Scholar 

  15. Lee N, Harris J, Garden AS, et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol. 2009;27(22):3684.

    Article  Google Scholar 

  16. Peng G, Wang T, Yang K, et al. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol. 2012;104(3):286–93.

    Article  Google Scholar 

  17. Lee AW, Tung SY, Chan AT, et al. A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma. Radiother Oncol. 2011;98(1):15–22.

    Article  Google Scholar 

  18. Lee AW, Ngan RK, Tung SY, et al. Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma. Cancer. 2015;121(8):1328–38.

    Article  CAS  Google Scholar 

  19. Lee AW, Sze WM, Au JS, et al. Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys. 2005;61(4):1107–16.

    Article  Google Scholar 

  20. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998;16(4):1310–7.

    Article  CAS  Google Scholar 

  21. Chen Q, Wen Y, Guo L, et al. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. J Natl Cancer Inst. 2011;103(23):1761–70.

    Article  Google Scholar 

  22. Lee AW, Tung SY, Ngan RK, et al. Factors contributing to the efficacy of concurrent–adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 trials. Eur J Cancer. 2011;47(5):656–66.

    Article  CAS  Google Scholar 

  23. Liang H, Xia W, Lv X, et al. Concurrent chemoradiotherapy with 3-weekly versus weekly cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial (ChiCTR-TRC-12001979). J Clin Oncol. 2017;35(15 Suppl):6006.

    Article  Google Scholar 

  24. Lee JY, Sun J, Oh DR, et al. Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: a multicenter randomized phase II trial (KCSG-HN10-02). Radiother Oncol. 2016;118(2):244–50.

    Article  CAS  Google Scholar 

  25. Zhang L, Zhao C, Peng P, et al. Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results. J Clin Oncol. 2005;23(33):8461–8.

    Article  CAS  Google Scholar 

  26. Wu X, Huang PY, Peng PJ, et al. Long-term follow-up of a phase III study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma. Ann Oncol. 2013;24(8):2131–6.

    Article  CAS  Google Scholar 

  27. Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P, et al. Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomised, non-inferiority, open trial. Eur J Cancer. 2007;43(9):1399–406.

    Article  CAS  Google Scholar 

  28. Chen L, Hu C, Chen X, Hu G, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2012;13(2):163–71.

    Article  Google Scholar 

  29. Chen L, Hu C, Chen X, et al. Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase 3 multicentre randomised controlled trial. Eur J Cancer. 2017;75:150–8.

    Article  CAS  Google Scholar 

  30. Blanchard P, Lee A, Marguet S, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol. 2015;16(6):645–55.

    Article  Google Scholar 

  31. Ribassin-Majed L, Marguet S, Lee AW, et al. What is the best treatment of locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis. J Clin Oncol. 2017;35:498.

    Article  Google Scholar 

  32. Chan AT, Lo YD, Zee B, et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst. 2002;94(21):1614–9.

    Article  CAS  Google Scholar 

  33. Chan AT, Ngan RK, Hui EP, et al. A multicenter randomized controlled trial (RCT) of adjuvant chemotherapy (CT) in nasopharyngeal carcinoma (NPC) with residual plasma EBV DNA (EBV DNA) following primary radiotherapy (RT) or chemoradiotherapy (CRT). J Clin Oncol. 2017;35(15 Suppl):6002.

    Article  Google Scholar 

  34. Hui EP, Ma BB, Leung SF, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol. 2009;27:242.

    Article  CAS  Google Scholar 

  35. Sun Y, Li W, Chen N, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016;17(11):1509–20.

    Article  CAS  Google Scholar 

  36. Cao S, Yang Q, Guo L, et al. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase III multicentre randomised controlled trial. Eur J Cancer. 2017;75:14–23.

    Article  CAS  Google Scholar 

  37. Siala W, Mnejja W, Abid M, Ghorbel A, Frikha M, Daoud J. Thyroid toxicity after radiotherapy of nasopharyngeal carcinoma. Ann Endocrinol. 2011;72(1):19–23.

    Article  CAS  Google Scholar 

  38. Zhang A, Fan Y, Wang X, et al. Increased treatment-related mortality with additional cisplatin-based chemotherapy in patients with nasopharyngeal carcinoma treated with standard radiotherapy. Radiother Oncol. 2012;104(3):279–85.

    Article  Google Scholar 

  39. Sun X, Su S, Chen C, et al. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. Radiother Oncol. 2014;110(3):398–403.

    Article  Google Scholar 

  40. Ou X, Zhou X, Shi Q, et al. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost. Oncotarget. 2015;6(35):38381.

    Article  Google Scholar 

  41. Zhang L, Huang Y, Hong S, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet. 2016;388(10054):1883–92.

    Article  CAS  Google Scholar 

  42. Jin Y, Cai X, Shi Y, et al. Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 2012;138(10):1717–25.

    Article  CAS  Google Scholar 

  43. Chan AT, Hsu M, Goh BC, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol. 2005;23(15):3568–76.

    Article  CAS  Google Scholar 

  44. Chua DT, Wei WI, Wong MP, Sham JS, Nicholls J, Au GK. Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma. Head Neck. 2008;30(7):863–7.

    Article  Google Scholar 

  45. Ma B, Hui EP, King A, et al. A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy. Cancer Chemother Pharmacol. 2008;62(1):59–64.

    Article  CAS  Google Scholar 

  46. You B, Le Tourneau C, Chen EX, et al. A Phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma. Am J Clin Oncol. 2012;35(3):255–60.

    Article  CAS  Google Scholar 

  47. Elser C, Siu LL, Winquist E, et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol. 2007;25(24):3766–73.

    Article  CAS  Google Scholar 

  48. Xue C, Huang Y, Huang PY, et al. Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma. Ann Oncol. 2012;24(4):1055–61.

    Article  Google Scholar 

  49. Hui EP, Ma B, King AD, et al. Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation. Ann Oncol. 2011;22(6):1280–7.

    Article  CAS  Google Scholar 

  50. Lim W, Ng Q, Ivy P, et al. A phase II study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinoma. Clin Cancer Res. 2011;17(16):5481–9.

    Article  CAS  Google Scholar 

  51. Hui EP, Ma BB, Mo F, et al. Axitinib in recurrent or metastatic nasopharyngeal carcinoma (NPC): final result of a phase 2 clinical trial with pharmacokinetic (PK) correlation. Ann Oncol. 2016;27(6 Suppl):961.

    Google Scholar 

  52. Zhang J, Fang W, Qin T, et al. Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma. Med Oncol. 2015;32(3):86.

    Article  Google Scholar 

  53. Hsu C, Lee S, Ejadi S, et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1–positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study. J Clin Oncol. 2017;35(36):4050–6.

    Article  Google Scholar 

  54. Ma BB, Lim W, Goh B, et al. Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the Mayo Clinic phase 2 consortium (NCI-9742). J Clin Oncol. 2018;36:1412.

    Article  Google Scholar 

  55. Delord J, Hollebecque A, De Boer JP, et al. An open-label, multicohort, phase I/II study to evaluate nivolumab in patients with virus-associated tumors (CheckMate 358): efficacy and safety in recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC). J Clin Oncol. 2017;35(15 Suppl):6025.

    Article  Google Scholar 

  56. Hui EP, Taylor GS, Jia H, et al. Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients. Cancer Res. 2014;73(6):1676–88.

    Article  Google Scholar 

  57. Taylor GS, Jia H, Harrington K, et al. A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer. Clin Cancer Res. 2014;20(19):5009–22.

    Article  CAS  Google Scholar 

  58. Chia W, Teo M, Wang W, et al. Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma. Mol Ther. 2014;22(1):132–9.

    Article  CAS  Google Scholar 

  59. Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, Wang WY. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol. 2003;21(4):631–7.

    Article  Google Scholar 

  60. Chan AT, Teo PM, Ngan RK, et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol. 2002;20(8):2038–44.

    Article  CAS  Google Scholar 

  61. Chan AT, Leung SF, Ngan RK, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst. 2005;97(7):536–9.

    Article  CAS  Google Scholar 

  62. Wee J, Tan EH, Tai BC, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol. 2005;23(27):6730–8.

    Article  CAS  Google Scholar 

  63. Chen Y, Sun Y, Liang S, et al. Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China. Cancer. 2013;119(12):2230–8.

    Article  CAS  Google Scholar 

  64. Lee AW, Tung SY, Chua DT, et al. Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst. 2010;102(15):1188–98.

    Article  Google Scholar 

  65. Au E, Ang P. A phase II trial of 5-fluorouracil and cisplatinum in recurrent or metastatic nasopharyngeal carcinoma. Ann Oncol. 1994;5(1):87–9.

    Article  CAS  Google Scholar 

  66. Stein ME, Ruff P, Weaving A, Fried J, Bezwoda WR. A phase II study of cisplatin/ifosfamide in recurrent/metastatic undifferentiated nasopharyngeal carcinoma among young blacks in southern Africa. Am J Clin Oncol. 1996;19(4):386–8.

    Article  CAS  Google Scholar 

  67. Yeo W, Leung TW, Leung SF, et al. Phase II study of the combination of carboplatin and 5-fluorouracil in metastatic nasopharyngeal carcinoma. Cancer Chemother Pharmacol. 1996;38(5):466–70.

    Article  CAS  Google Scholar 

  68. Yeo W, Leung T, Chan A, et al. A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma. Eur J Cancer. 1998;34(13):2027–31.

    Article  CAS  Google Scholar 

  69. Tan E, Khoo KS, Wee J, et al. Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. Ann Oncol. 1999;10(2):235–7.

    Article  CAS  Google Scholar 

  70. McCarthy JS, Tannock IF, Degendorfer P, Panzarella T, Furlan M, Siu LL. A Phase II trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. Oral Oncol. 2002;38(7):686–90.

    Article  CAS  Google Scholar 

  71. Chua DT, Sham JS, Au GK. A phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma. Oral Oncol. 2005;41(6):589–95.

    Article  CAS  Google Scholar 

  72. Ngan R, Yiu H, Lau WH, et al. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study. Ann Oncol. 2002;13(8):1252–8.

    Article  CAS  Google Scholar 

  73. Ma BB, Tannock IF, Pond GR, Edmonds MR, Siu LL. Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma. Cancer. 2002;95(12):2516–23.

    Article  CAS  Google Scholar 

  74. Wang C, Chang J, Liu T, Lin C, Yu Y, Hong R. Phase II study of gemcitabine plus vinorelbine in the treatment of cisplatin-resistant nasopharyngeal carcinoma. Head Neck. 2006;28(1):74–80.

    Article  Google Scholar 

  75. Ma B, Hui EP, Wong S, et al. Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma—correlation with excision repair cross-complementing-1 polymorphisms. Ann Oncol. 2009;20(11):1854–9.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA

    Jonathan Pan, Jennifer Johnson & Athanassios Argiris

Authors
  1. Jonathan Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jennifer Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Athanassios Argiris
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium

    Jan B. Vermorken

  2. Department of Radiation Oncology, Charité University Medicine, Berlin, Germany

    Volker Budach

  3. Department of Otolaryngology , VU University Medical Center, Amsterdam, The Netherlands

    C. René Leemans

  4. Institut Roi Albert II, Université Catholique de Louvain , Louvain-la-Neuve, Belgium

    Jean-Pascal Machiels

  5. Department of Otorhinolarynology, University of Brescia, Brescia, Italy

    Piero Nicolai

  6. Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada

    Brian O'Sullivan

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Pan, J., Johnson, J., Argiris, A. (2018). Cytotoxic Chemotherapy and Targeted Therapy in Nasopharyngeal Cancer. In: Vermorken, J., Budach, V., Leemans, C., Machiels, JP., Nicolai, P., O'Sullivan, B. (eds) Critical Issues in Head and Neck Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-98854-2_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-98854-2_17

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-98853-5

  • Online ISBN: 978-3-319-98854-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation